Zimmer Biomet Holdings, Inc. (NYSE:ZBH) had its price target decreased by stock analysts at BMO Capital Markets from $140.00 to $135.00 in a research report issued on Thursday. The brokerage presently has an “outperform” rating on the medical equipment provider’s stock. BMO Capital Markets’ price objective would suggest a potential upside of 11.00% from the stock’s current price.

ZBH has been the topic of a number of other research reports. Zacks Investment Research downgraded Zimmer Biomet Holdings from a “hold” rating to a “strong sell” rating in a report on Tuesday, August 8th. Morgan Stanley upped their target price on Zimmer Biomet Holdings from $137.00 to $150.00 and gave the stock an “overweight” rating in a report on Monday, July 17th. Oppenheimer Holdings, Inc. set a $137.00 target price on Zimmer Biomet Holdings and gave the stock a “buy” rating in a report on Monday, August 14th. Canaccord Genuity downgraded Zimmer Biomet Holdings from a “buy” rating to a “hold” rating and reduced their target price for the stock from $141.00 to $135.00 in a report on Friday, July 28th. Finally, Needham & Company LLC reiterated a “strong-buy” rating and set a $153.00 target price on shares of Zimmer Biomet Holdings in a report on Wednesday, July 12th. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. Zimmer Biomet Holdings has an average rating of “Hold” and an average target price of $135.60.

Zimmer Biomet Holdings (NYSE:ZBH) last posted its earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.02). Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The firm had revenue of $1.82 billion for the quarter, compared to analysts’ expectations of $1.83 billion. During the same quarter last year, the company posted $1.79 EPS. The firm’s revenue was down .8% on a year-over-year basis.

COPYRIGHT VIOLATION NOTICE: This article was first reported by American Banking News and is owned by of American Banking News. If you are reading this article on another site, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/11/02/zimmer-biomet-holdings-inc-zbh-price-target-cut-to-135-00.html.

A number of hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its position in Zimmer Biomet Holdings by 4.1% in the 2nd quarter. BlackRock Inc. now owns 17,419,463 shares of the medical equipment provider’s stock valued at $2,236,657,000 after acquiring an additional 679,080 shares in the last quarter. Vanguard Group Inc. lifted its position in Zimmer Biomet Holdings by 2.6% in the 2nd quarter. Vanguard Group Inc. now owns 13,380,517 shares of the medical equipment provider’s stock valued at $1,718,057,000 after acquiring an additional 339,106 shares in the last quarter. State Street Corp lifted its position in Zimmer Biomet Holdings by 2.4% in the 1st quarter. State Street Corp now owns 8,193,165 shares of the medical equipment provider’s stock valued at $1,000,463,000 after acquiring an additional 191,747 shares in the last quarter. Longview Partners Guernsey LTD lifted its position in Zimmer Biomet Holdings by 17.7% in the 3rd quarter. Longview Partners Guernsey LTD now owns 7,506,684 shares of the medical equipment provider’s stock valued at $878,958,000 after acquiring an additional 1,128,973 shares in the last quarter. Finally, American Century Companies Inc. lifted its position in Zimmer Biomet Holdings by 8.1% in the 3rd quarter. American Century Companies Inc. now owns 4,165,353 shares of the medical equipment provider’s stock valued at $487,721,000 after acquiring an additional 311,654 shares in the last quarter. 85.26% of the stock is currently owned by institutional investors and hedge funds.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Analyst Recommendations for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.